A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine

NCT03900572 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

HPV Infections

Interventions

BIOLOGICAL: HPV Vaccine
DRUG: Placebo

Sponsor

Shanghai Zerun Biotechnology Co.,Ltd